Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation-Reference-Cited by-同舟云学术

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation

Published:2022-05-17 Issue:10 Volume:6 Page:3053-3057
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Lorentino Francesca¹²,Xue Elisabetta¹,Mastaglio Sara¹,Giglio Fabio¹,Clerici Daniela¹,Farina Francesca¹,Piemontese Simona¹,Bruno Alessandro¹,Lazzari Lorenzo¹,Ruggeri Annalisa¹,Guggiari Elena¹,Lunghi Francesca¹,Assanelli Andrea A.¹,Marktel Sarah¹,Marcatti Magda¹,Carrabba Matteo G.¹^ORCID,Bernardi Massimo¹^ORCID,Corti Consuelo¹^ORCID,Peccatori Jacopo¹,Ciceri Fabio¹³,Greco Raffaella¹^ORCID,Lupo-Stanghellini Maria Teresa¹^ORCID

Affiliation:

1. Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy;

2. PhD Program in Public Health, Department of Medicine and Surgery, University of Milano-Bicocca, Italy; and

3. School of Medicine, University Vita-Salute San Raffaele, Milan, Italy

Publisher

American Society of Hematology

Subject

Hematology

Link

https://ashpublications.org/bloodadvances/article-pdf/6/10/3053/1897662/advancesadv2021006213.pdf

Reference25 articles.

1. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide;Luznik;Biol Blood Marrow Transplant.,2008